Page last updated: 2024-10-28

hydralazine and Myelodysplastic Syndromes

hydralazine has been researched along with Myelodysplastic Syndromes in 2 studies

Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.

Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.

Research Excerpts

ExcerptRelevanceReference
"The hydralazine dose was given according with the acetylator phenotype, and valproate was dosed at 30 mg/kg/day."2.76Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. ( Arias-Bofill, D; Candelaria, M; Cervera, E; de la Cruz-Hernández, E; Dueñas-Gonzalez, A; González-Fierro, A; Herrera, A; Labardini, J; Pérez-Cárdenas, E; Taja-Chayeb, L; Trejo-Becerril, C; Vidal, S, 2011)
"Hydralazine was dosed according to the acetylation genotype of patients (slow acetylators 83 mg daily; fast acetylators 182 mg daily), and valproate was dosed at 30 mg/kg/day."1.46Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS). ( Burgos, S; Candelaria, M; Dueñas-Gonzalez, A; Espinoza, R; Ponce, M, 2017)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Candelaria, M2
Burgos, S1
Ponce, M1
Espinoza, R1
Dueñas-Gonzalez, A2
Herrera, A1
Labardini, J1
González-Fierro, A1
Trejo-Becerril, C1
Taja-Chayeb, L1
Pérez-Cárdenas, E1
de la Cruz-Hernández, E1
Arias-Bofill, D1
Vidal, S1
Cervera, E1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
"Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652]Phase 3230 participants (Anticipated)Interventional2015-07-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for hydralazine and Myelodysplastic Syndromes

ArticleYear
Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
    Annals of hematology, 2011, Volume: 90, Issue:4

    Topics: Adult; Aged; Azacitidine; Cytogenetic Analysis; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DN

2011

Other Studies

1 other study available for hydralazine and Myelodysplastic Syndromes

ArticleYear
Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
    Annals of hematology, 2017, Volume: 96, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use Tr

2017
chemdatabank.com